M

Monte Rosa Therapeutics Inc
NASDAQ:GLUE

Watchlist Manager
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Watchlist
Price: 4.49 USD -1.75%
Market Cap: 276.2m USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one GLUE stock under the Base Case scenario is 5.53 USD. Compared to the current market price of 4.49 USD, Monte Rosa Therapeutics Inc is Undervalued by 19%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GLUE Relative Value
Base Case
5.53 USD
Undervaluation 19%
Relative Value
Price
M
Worst Case
Base Case
Best Case

Valuation Multiples

1.7
P/S
P/S
Price to Sales
1.7
vs History
26
vs Industry
29
Median 3Y
0
Median 5Y
0
Industry
7.2
Forward
2.6
More Details
44.9
P/E
P/E
Price to Earnings
44.9
vs History
2
vs Industry
Median 3Y
-2.7
Median 5Y
-3.3
Industry
23.2
Forward
-3.5
More Details
8
P/OCF
P/OCF
Price to OCF
8
vs History
7
vs Industry
Median 3Y
-4.2
Median 5Y
-4.8
Industry
19.3
More Details
9.1
P/FCFE
P/FCFE
Price to FCFE
9.1
vs History
6
vs Industry
Median 3Y
-3.6
Median 5Y
-4.2
Industry
22.5
More Details
1
P/B
P/B
Price to Book Value
1
vs History
88
vs Industry
45
Median 3Y
1.4
Median 5Y
1.5
Industry
2.7
More Details
Negative
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
41
Median 3Y
0
Median 5Y
0
Industry
7.5
Forward
-0.5
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.4
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
26
Median 3Y
-0.9
Median 5Y
-1.1
Industry
4.6
Forward
0.9
More Details
23.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
23.4
vs History
4
vs Industry
25
Median 3Y
-0.7
Median 5Y
-0.9
Industry
4.5
Forward
0.7
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
26
Median 3Y
-1.2
Median 5Y
-1.5
Industry
4.9
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
23
Median 3Y
-1.1
Median 5Y
-1.3
Industry
3.7
More Details
Negative
EV/IC
EV/IC
Enterprise Value to IC
N/A
vs History
vs Industry
49
Median 3Y
1.3
Median 5Y
1.5
Industry
4.9
More Details

Multiples Across Competitors

GLUE Competitors Multiples
Monte Rosa Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
276.2m USD 1.7 44.9 -8.1 23.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 559 828.3 -164 257.7 -199 461.3 -197 185.2
US
Abbvie Inc
NYSE:ABBV
327.6B USD 5.7 78.9 15.1 22.3
US
Amgen Inc
NASDAQ:AMGN
155.7B USD 4.6 26.2 14.2 23.3
US
Gilead Sciences Inc
NASDAQ:GILD
134.5B USD 4.7 22.5 9.8 13.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.2B USD 10.4 -116.5 24.7 25.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 038.5 -520.2 -566.4 -551.3
AU
CSL Ltd
ASX:CSL
115.6B AUD 4.9 27.4 16.9 21.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
55.6B USD 3.9 12.4 11 12.3
US
Seagen Inc
F:SGT
39.3B EUR 19.6 -60.2 -64.9 -58.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
40.7B USD 17.3 -150.9 -676.2 -338.8
P/E Multiple
Earnings Growth PEG
US
M
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Average P/E: 35.4
44.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -164 257.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
78.9
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.2
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
22.5
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -116.5 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -520.2 N/A N/A
AU
CSL Ltd
ASX:CSL
27.4
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.4
7%
1.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -150.9 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
M
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Average EV/EBITDA: 15.3
Negative Multiple: -8.1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -199 461.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.1
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.2
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.8
6%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.7
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -566.4 N/A N/A
AU
CSL Ltd
ASX:CSL
16.9
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.9 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -676.2 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
M
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Average EV/EBIT: 20.3
23.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 185.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.3
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.3
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.6
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.9
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -551.3 N/A N/A
AU
CSL Ltd
ASX:CSL
21.2
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.3
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.5 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -338.8 N/A N/A

See Also

Summary
GLUE intrinsic value, competitors valuation, and company profile.
DCF Valuation
GLUE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GLUE stock valuation using valuation multiples.
Wall Street Estimates
GLUE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GLUE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 262,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.